IDEMIA
5.10.2020 18:21:12 CEST | Business Wire | Press release
A world first, remote smartphone-based passenger biometric registration gives passengers a smoother and contactless experience from ID registration until they board. Passenger faces - a genuine Open Sesame throughout the airport - are recorded at home on Mona, Lyon Airport’s smartphone app. Having registered in advance, passengers can put their travel documents away as they pass unhindered through the airport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201005005759/en/
Passenger registration is secured by a biometric match between their smartphone-based face and scans of their ID document and boarding card. This totally accurate and reliable identity management system that IDEMIA has perfected lets passengers speed through all identity control points.
RESA’s latest automatic and biometric compact gate dubbed Major eGate , which caters for disabled people too, comes with an integrated camera so that passengers can pass through to the security restricted area and then board their plane based merely on facial recognition.
IDEMIA’s system is universal, secure and works on all airline systems thanks to RESA’s IATA-certified CUPPS system. This will be available at Lyon Airport for Transavia and TAP flights to Portugal.
While this new service is subject to formal CNIL1 approval, to date CNIL has recommended it to safeguard passenger data and rights.
IDEMIA Executive VP Identity and Public Safety Philippe Barreau said: “As biometric security solutions expert, we are thrilled to deliver a world first alongside our customers Vinci Airports and Lyon Airport and our partner RESA. This trial harnesses contactless biometric technology that gives users an unrivaled airport experience without letting up one jot on security. This bears out our capacity to constantly innovate to safeguard passenger trust and help pave the way for even smoother and more secure future travel .”
RESA CEO Renaud Willard said: “Current covid restrictions forced us to rethink how to take care of passengers and their interactions with airport security staff and equipment. The biometric trial underway at Lyon Airport was made possible by French industrial collaboration, whereby hi-tech saved the day despite the current pandemic and economic crisis. We have shown here that passengers can pass through airport checks fully contactless and without handing over paper documents while shoring up security to boot.”
Vinci Airports France & Americas Area Director Valérie Vesque-Jeancard said: “We are thrilled to launch MONA today, a world first, at a time when airports need game-changing innovations so they can give passengers an even safer, more enjoyable and personalized experience. I warmly congratulate all staff involved including IDEMIA and RESA people, who managed to overcome tough restrictions these last few months and deliver a great trial in barely a year.”
IDEMIA provides both rapid and safe passenger flow solutions to countless airports around the world and manages 30-plus government border control programs. In 2017, IDEMIA installed a facial recognition-based biometric ID control system in Terminal 4 of Singapore’s Changi Airport, from baggage check-in right through to aircraft boarding, including going airside and border crossing. The Company has regularly conducted facial recognition technology trials to make boarding smoother.
RESA’s expertise lies in introducing biometric technology to authenticate airport security staff, who need to connect to airport IT systems. RESA is currently engaged in introducing such technology on top of existing passenger airport systems. Previously, the firm has conducted several pilot tests including in Singapore and Paris airports.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
About RESA
Backed by 30 years of experience and 1,000-plus software programs installed in 62 countries, RESA is one of the world’s top airport and airline systems developers.
The firm is an innovative Vendée-based small business that develops, sells and maintains a broad range of integrated software covering all airport system needs, including passenger check-in and boarding, baggage tracing and reconciliation, passenger tracking, automatic gates, self-service kiosks and biometrics, flight management, resource allocation, billing, statistics, business intelligence and messaging.
__________________________________
1
France’s national authority responsible for data privacy
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005759/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom